Chronic myeloid leukaemia – Life with Disease – Overview of Information and Clinical Research
Chronic myeloid leukemia is a slowly developing blood cancer that affects white blood cells in the bone marrow.
A comprehensive overview of chronic myeloid leukaemia (CML), covering its pathogenesis, clinical phases, prognosis, complications, daily life impact, and current research avenues including registered therapies and ongoing clinical trials.
CML transforms from a once life‑threatening disease to a manageable chronic illness thanks to targeted tyrosine‑kinase inhibitors, profoundly changing patient prognosis and quality of life.
Evidence level: Megerősített klinikai bizonyíték. Több vagy erősebb humán vizsgálat támogatja.
Related signals
- Treatment of chronic myeloid leukemia chronic phase patients in third-line setting and beyond: recommendations from a Belgian expert panel in 2025
- Chronic myeloid leukemia: Current guidelines for diagnosis and management
- Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment‑free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co‑primary endpoint
- Information about Project 4: Chronic myeloid leukemia (CML)
- Prevalence and characterization of germline RAS pathway variants in children with chronic myeloid leukemia